Medical Research, Oncologist

How Mikhail Blagosklonny Is Seeking To Improve People’s Lives

Mikhail Blagosklonny, Ph.D., is a leading scientist who is a Professor at the Roswell Park Cancer Institute. He conducts research into cancer and the aging process in order to help people live fuller, longer lives free of cancer and other age-related diseases. He is also the editor of a number of peer-reviewed medical journals such as the often cited Oncotarget.

Dr. Blagosklonny’s alma mater is First Pavlov State Medical University of St. Petersburg. He graduated from this Russian university with both his medical degree and Ph.D. in Cardiology and Experimental Medicine. He moved to the United States in 2002 when he was named an Associate Professor of Medicine by the New York Medical College. After he left this position he joined the Ordway Research Institute. It was in 2009 that he left to take his current position at the Roswell Park Cancer Institute which is located in Buffalo, New York. View Mikhail’s profile in LinkedIn

Dr. Mikhail Blagosklonny is well-known in the longevity research field as a huge proponent of researching Rapamycin as an effective way to slow or even halt the aging process. Rapamycin is a drug that is used to treat cancer; because of its possible role in TOR Signaling, it could also be a treatment for aging according to Dr. Blagosklonny’s extensive research in the drug.

While he has had more than 270 peer-reviewed research articles published himself, Dr. Mikhail Mikhail Blagosklonny is also very active as a medical journal founder and editor. He is involved with a number of peer-reviewed journals including Oncotarget, Aging, Oncoscience, Cancer Biology & Therapy, Autophagy, Cell Death and Differentiation and others as well. His ultimate goal is to provide people with a life that is free of disease. To do so he publishes research articles that are provided in a timely fashion and that are made widely available. Another mission of Dr. Blagosklonny’s is to remove the borders that tend to exist between clinical specialties and instead foster a more collaborative environment which leads to greater advances in the field of medicine. Visit ResearchGate.Net to learn more about Mikhail’s latest work.

Medical Research

Oncotarget: Current New About Breakthroughs In Medical Science

Ignorance is one cause of sickness and premature death for millions of people every year. Not knowing you have a problem or what research and other actions on Twitter are being taken to address it prevents many people from living longer, happier, more productive lives. The weekly peer-reviewed medical journal Oncotarget has as its mission helping remove that ignorance by providing people with information on the latest breakthroughs in oncology and age related illnesses. Founded in 2010, Oncotarget offers open access to scientists and researchers working on the cutting-edge of medical science to share their results.

The weekly journal, published by Impact Journals, covers topics related to every aspect of oncology research. It’s abstracted and indexed in numerous places including BIOSIS Previews, Index Medicus/MEDLINE/PubMed, BIOSIS Previews, Scopus and the Science Citation Index Expanded. The journal on YouTube currently has two editors-in-chief. They are Mikhail Blagosklonny and Andrei Gudkov. Under their direction Oncotarget has expanded its range and now publishes papers on topics like:

1. Gerotarget/Aging
2. Cardiology
3. Cel & Molecular Biology
4. Endocrinology
5. Immunology/Microbiology
6. Metabolism
7. Neuropathology/Neuroscience
8. Pharmacology

That has helped to expand the publication’s audience and its impact. Oncotarget is available online or in a printed version upon special request.

The term “oncotarget” is one that’s familiar to people involved with issues related to cancer and aging, microbes, atherosclerosis, neurodegeneration, neurons and lymphocytes. Oncotarget deals with molecules and pathways as well as cellular functions. It’s a multidisciplinary traditional journal that rapidly and widely disseminates scientific results after insightful review. The publication aims to eliminate borders between specialties to maximize the impact the research has and create a link between biomedical science’s many different fields. See:

Another of Oncotarget’s goals is to help people far and wide improve their results when they fight disease using basic and clinical science. Sharing these amazing discoveries as quickly as possible is just another way the publication fulfills its mission to provide the public with timely information that can help improve the quality of people’s lives. Oncotarget is run by a leadership group that contains some of the world’s most prominent scientists, researchers and physicians. They help to ensure the journal is making a contribution to scientific progress on The publication’s ultimate goal is life without disease.

The journal has published many groundbreaking papers. Those papers have helped expand the boundaries of what’s commonly accepted medical science and benefitted many people.